Canurta Advances Clinical Research and IP Strategy Through National Conferences and Strategic Funding

Canurta Showcases at Accelerating Clinicial Trials (ACT) Canada

ACT is a consortium of researchers, patient-partners, healthcare professionals, the biotechnology industry, and government working together to improve the efficiency of randomized clinical trials.

From April 17-18, Canurta CEO Akeem Gardner and Research Associate Kelly Boddington shared Canurta's clinical pipeline and discussed innovations in our research methodologies.

Bloom Burton & Co. Healthcare Investor Conference

From April 25-26, Canada’s premier publicly-traded and venture-backed private companies as well as the most promising pre-venture companies in the healthcare industry gathered in Toronto.

Canurta interacted with Canadian, U.S. and international investors who are interested in the latest developments in Canadian healthcare.

Canurta's April Milestones: Accelerating Research and Prioritizing IP Strategies

Science

• Shipped product to TransBIOTech to begin pharmacokinetic and cytotoxicity trials

• Received data back from our two C. Elegans (nematode) trials on neurodegenerative disorders

Business Development

• Received funding from The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) IP to help execute the actions prioritized in our IP strategy